INmune Bio, Inc. (NASDAQ:INMB) Short Interest Up 7.0% in January

INmune Bio, Inc. (NASDAQ:INMB) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 4,280,000 shares, a growth of 7.0% from the December 31st total of 4,000,000 shares. Based on an average daily volume of 229,900 shares, the short-interest ratio is presently 18.6 days.

INmune Bio Price Performance

INMB stock opened at $9.76 on Tuesday. The business’s fifty day moving average price is $5.73 and its two-hundred day moving average price is $6.04. The stock has a market capitalization of $216.40 million, a price-to-earnings ratio of -4.48 and a beta of 1.78. INmune Bio has a fifty-two week low of $4.32 and a fifty-two week high of $14.74.

Wall Street Analysts Forecast Growth

INMB has been the topic of several research analyst reports. Alliance Global Partners began coverage on INmune Bio in a research note on Monday, October 21st. They issued a “buy” rating and a $20.00 price objective on the stock. Rodman & Renshaw initiated coverage on INmune Bio in a report on Tuesday, January 28th. They set a “buy” rating and a $23.00 price target for the company. Finally, RODMAN&RENSHAW raised shares of INmune Bio to a “strong-buy” rating in a research report on Tuesday, January 28th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $20.75.

Institutional Trading of INmune Bio

A number of institutional investors have recently bought and sold shares of INMB. Financial Advocates Investment Management raised its position in shares of INmune Bio by 17.4% in the third quarter. Financial Advocates Investment Management now owns 13,500 shares of the company’s stock valued at $73,000 after buying an additional 2,000 shares in the last quarter. Jane Street Group LLC acquired a new position in INmune Bio in the 3rd quarter valued at $79,000. Rhumbline Advisers lifted its position in shares of INmune Bio by 16.9% during the 4th quarter. Rhumbline Advisers now owns 16,744 shares of the company’s stock valued at $78,000 after acquiring an additional 2,424 shares during the period. Sanctuary Advisors LLC acquired a new stake in shares of INmune Bio during the 3rd quarter worth $113,000. Finally, Barclays PLC grew its holdings in shares of INmune Bio by 601.9% during the 3rd quarter. Barclays PLC now owns 29,044 shares of the company’s stock worth $157,000 after purchasing an additional 24,906 shares in the last quarter. Institutional investors own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.